Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:TBPH

Theravance Biopharma Q3 2026 Earnings Date & Estimates

Theravance Biopharma logo
$17.03 0.00 (0.00%)
As of 10/23/2026

Theravance Biopharma is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Theravance Biopharma in Q3 2026

Theravance Biopharma is expected to post earnings of $0.24 per share on revenue of $21.95 million. In the same quarter a year earlier Theravance Biopharma reported $0.07 per share on revenue of $19.99 million. Theravance Biopharma last reported on August 10, 2026, posting -$0.11 per share and missing the $0.0725 consensus estimate. Theravance Biopharma has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.24
Expected Revenue
$21.95 million
Prior-Year EPS
$0.07
Prior-Year Revenue
$19.99 million
Expected EPS Growth
+242.9%
Expected Revenue Growth
+9.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.11 (Missed by -$0.1825)
Last Quarter Revenue
$20.73 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Theravance Biopharma Q3 2026 Earnings FAQ

Theravance Biopharma (NASDAQ:TBPH) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Theravance Biopharma's Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Theravance Biopharma to post earnings of $0.24 per share for Q3 2026.

The consensus revenue estimate for Theravance Biopharma is $21.95 million for Q3 2026.

Theravance Biopharma Earnings Headlines

Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Rated "Hold" by Wall Street Brokerages
October 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31144799
Analyzing Chugai Pharmaceutical (OTCMKTS:CHGCY) & Theravance Biopharma (NASDAQ:TBPH)
October 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31138550
Nvidia's $550 Trillion Problem
Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Alphabet about $4.1 trillion. Microsoft about $3.8 trillion. So what would it take to repeat Nvidia's run? A 100x gain from here puts Nvidia near $550 trillion. Nothing in history has ever been worth that. Big money in Nvidia has already been made. By the people who bought it years ago. But that does not mean the AI boom is finished. It means the opportunity has moved underneath it... to the layer every AI company has to pay to use.tc pixel
October 26 at 1:00 AM  |  Decentralized Masters (Ad)
Theravance Biopharma (NASDAQ:TBPH) & ARS Pharmaceuticals (NASDAQ:SPRY) Head-To-Head Review
October 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31132929
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell Small Cap Completeness Index
September 24, 2026  |  marketscreener.comM
Zymeworks Inc. (NasdaqGS:ZYME) hat Theravance Biopharma, Inc. (NasdaqGM:TBPH) übernommen.
September 24, 2026  |  de.marketscreener.comD
See More Theravance Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email.

About Theravance Biopharma

Theravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on respiratory disorders and other conditions where there is a significant unmet medical need. The company’s research and development activities have historically centered on therapies designed to improve lung function and address chronic respiratory disease.

Its principal marketed product is Yupelri (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Yupelri is commercialized in collaboration with Viatris. Theravance Biopharma also receives royalty revenues connected with Trelegy Ellipta, an inhaled treatment for COPD and asthma developed and commercialized by GSK under a licensing arrangement.

Theravance Biopharma was established following the 2014 separation of the biopharmaceutical operations of Theravance, Inc. from the company’s royalty-focused business. The company is headquartered in Dublin, Ireland, and serves international markets primarily through commercial and development partnerships. Rick E. Winningham has served as the company’s chief executive officer and chairman.

View Theravance Biopharma Profile
Earnings Tools